Mavrilimumab
- Generic Name
- Mavrilimumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1085337-57-0
- Unique Ingredient Identifier
- 1158JD1P9A
- Background
Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
- Associated Conditions
- -
- Associated Therapies
- -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Kristin Hudock
- Target Recruit Count
- 1
- Registration Number
- NCT04492514
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 2
- Registration Number
- NCT04463004
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 815
- Registration Number
- NCT04447469
- Locations
- 🇵🇪
Hospital Nacional Cayetano Heredia, San MartÃn De Porres, Peru
🇧🇷Hospital Cardio Pulmonar, Salvador, Bahia, Brazil
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT04399980
- Locations
- 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
🇺🇸Cleveland Clinic Health System, Cleveland, Ohio, United States
Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 50
- Registration Number
- NCT04397497
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
🇮🇹IRCCS Policlinico San Donato, San Donato, MI, Italy
🇮🇹IRCCS Istituto Ortopedico Galeazzi, Milano, Italy
A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- MedImmune Ltd
- Target Recruit Count
- 38
- Registration Number
- NCT00771420
- Locations
- 🇩🇪
Charite Research Organization GmbH, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.